Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of the year

Read Time:7 Second

Eli Lilly is racing to market donanemab for Alzheimer’s after Eisai and Biogen’s drug for the disease, Leqembi, won FDA approval this month.

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

Birria has become a popular protein option for tacos, quesadillas, grilled cheese and even ramen.

Visa and MasterCard have surged in the past two decades, reaching a combined $1 trillion market cap. That has attracted...

Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for patients...

Levi Strauss created fan buzz on Monday after teasing a future collaboration with Beyoncé through a post on Instagram.

The new offer includes higher pay increases, reinstated annual bonuses and an increased ratification bonus, among other changes, Boeing said...

Southwest will provide more detail about its plans to raise profits at an investor day on Sept. 26.